priaxon.com
Logo


Priaxon is a drug discovery company for small molecule therapeutics. Using a novel proprietary technology Priaxon opens up a new dimension in the development of small molecule inhibitors for protein protein interactions - a future target class in oncology.

The partnering of the mdm2/p53 inhibitor program with Boehringer Ingelheim highlights the performance and potential of Priaxon's drug discovery platform.

In parallel Priaxon is focusing on the development of hybrid antibiotics for nosocomial infections and is working on different target classes on the basis of various grants and cooperations.

News NEWS

Jun 14, 2010
Faron and Priaxon: Cardiovascular Deseases Research Collaboration in the field of PPI

Faron and Priaxon announce a collaboration to generate a new class of AOC3/SSAO antagonist

read more
Apr 22, 2010
Drug Discovery Chemistry being held April 27-29th in San Diego, CA

Meet Priaxon at Drug Discovery Chemistry, April 27-29th in San Diego, CA

read more
Mar 03, 2010
Priaxon at the the 8th World Congress on Trauma, Shock, Inflammation and Sepsis – TSIS 2010

Priaxon presents lecture on the topic of ‘Hybrid Antibiotics: Dual Mode of Action for the Treatment of Nosocomial Infections with Multi-Resistant Germs’ at TSIS 2010

read more